In this online CME self-learning program:
Type 2 diabetes mellitus (T2DM), the sixth leading cause of death in the U.S., is directly responsible for more then 73,000 deaths annually and is a contributing factor in more than 220,000 deaths. More than 20 million Americans have diabetes of which 6 million are undiagnosed. It is the leading cause of kidney failure and blindness in adults. Evidence-based guidelines for the management of T2DM focus on three areas: lifestyle changes (that include diet, exercise and weight loss); management of cardiovascular disease risk factors (including hypertension, dyslipidemia and microalbuminuria with the use of aspirin, statins and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers); and management of blood glucose levels with pharmacotherapy.
The Consensus Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes have identified a number of agents as either first- or later-line. Partially in response to this Consensus Statement, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) convened a consensus panel and issued their statement on glycemic control in T2DM. In developing their treatment algorithm, they set as priorities minimizing the risk and severity of hypoglycemia and minimizing the risk and magnitude of weight gain. Consequently, the AACE/ACE Diabetes algorithm for glycemic control features a more prominent role for certain agents given their impact on weight and their relative risk of hypoglycemia. The relatively recent nature of these guidelines’ updates implicitly suggests a practice gap that may be remedied by raising awareness through continuing education learning activities.
One other practical aspect highlighting a gap in care is one of demographic gaps in care. The literature suggests that: there are or may be emerging or existing patterns of racial-, ethnic-, gender-, age-, and geographic-based disparities in healthcare and treatment of patients with T2DM; race- and ethnicity-based discrimination within the healthcare environment are associated with disparities in care; and that such discrimination is associated with both worse chronic health condition control and a higher incidence catastrophic health events. Therefore, in addition to a therapeutic review, this program also attempts to examine the role of demographic-based barriers to care of patients with T2DM and strategies to minimize or alleviate those disparities.
Agenda
Healthcare professionals who include certified diabetes educators, diabetes nurse educators, diabetologists, endocrinologists, family medicine practitioners, and those who otherwise commonly care for patients with diabetes or who frequently encounter them or their caregivers in practice.
This program is supported by educational grants from Novo Nordisk.
Release Date: December 12, 2012 -- Expiration Date: December 12, 2014
Faculty: Ann Lynch, PharmD
By the end of the session the participant will be able to:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
THE ACCREDITATION FOR THIS PROGRAM HAS EXPIRED, NO CERTIFICATE WILL BE ISSUED.
As an provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is our policy to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Faculty Disclosure: Ann Lynch, PharmD reports that she has no relevant financial disclosures.
Disclosures of Educational Planner: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Novo Nordisk, the commercial supporter of this program.
Commercial Support Disclosure: This program is supported by educational grants from Novo Nordisk.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.